Digest Network Come funziona
Network
/
Società
Pa
Non verificato

Palleon Pharmaceuticals

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaOncologiaSalute

7 comunicati stampa

Guarda tutti i comunicati
20/04/2026
Eventi
Industria
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Palleon Pharmaceuticals Presents First-in-Class B7-H3 Targeted Sialidase at the 2026 AACR Annual Meeting
Fonte
Palleon Pharmaceuticals
Emittente
Business Wire
1.00
0
02/04/2026
Eventi
Industria
Oncologia
Salute
Sanità
Medicina - Varie
Farmaceutica
Biotecnologia
Palleon Pharmaceuticals to Present on Development of HLX316/E-688 at the American Association for Cancer Research (AACR) Annual Meeting
Fonte
Palleon Pharmaceuticals
Emittente
Business Wire
1.00
0
22/10/2025
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Industria
Eventi
Palleon Pharmaceuticals to Present on Development of HLX79/E-602 in Autoimmune Disease at the American College of Rheumatology Convergence Annual Meeting and the American Society of Nephrology Kidney Week
Fonte
Palleon Pharmaceuticals
Emittente
Business Wire
1.00
0
07/08/2025
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Industria
Palleon Pharmaceuticals Announces First Patient Dosed in Phase 2 Clinical Trial of E-602 (HLX79), a Potential First-In-Class Treatment for Active Glomerulonephritis
Fonte
Palleon Pharmaceuticals
Emittente
Business Wire
1.00
0
02/04/2025
Industria
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Palleon Pharmaceuticals Announces NMPA IND Clearance to Proceed with Phase 2 Clinical Trial of E-602 (HLX79), a First-In-Class Treatment for Autoimmune Diseases
Fonte
Palleon Pharmaceuticals
Emittente
Business Wire
1.00
0
19/12/2024
Scienza
Biotecnologia
Farmaceutica
Oncologia
Salute
Medicina - Varie
Mercato del lavoro
Industria
Palleon Pharmaceuticals and Henlius Collaborate to Advance Glycan Editing as a Treatment for Autoimmune Diseases
Fonte
Palleon Pharmaceuticals
Emittente
Business Wire
1.00
0
08/11/2024
Eventi
Industria
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Palleon Pharmaceuticals Presents Results from the Phase 1/2 GLIMMER-01 Trial of E-602 in Combination with Cemiplimab in Patients with Solid Tumors at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
Fonte
Palleon Pharmaceuticals
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0